David Quinn Gacioch
Subscribe to David Quinn Gacioch's Posts
Dave Gacioch counsels clients across the health care industry and beyond on compliance and risk management issues. He also assists clients in conducting internal investigations and represents them in matters involving government investigations, enforcement actions and civil litigation. Read David Gacioch's full bio.
Healthcare Enforcement Quarterly Roundup – Q2 2019
By Amandeep S. Sidhu, David Quinn Gacioch, Drew Elizabeth McCormick, Edward G. Zacharias, Irene A. Firippis, Jennifer Aronoff, Jennifer B. Routh, Katrina Rogachevsky, Lauren Evans, Laura McLane, Marshall E. Jackson, Jr., Paul M. Thompson, Sophia A. Luby, Theodore Alexander and Tony Maida on Aug 27, 2019
Posted In Additional Compliance Resources, Compliance Developments, Other Notable Enforcement Actions, Pharmaceuticals
In this second installment of the Healthcare Enforcement Quarterly Roundup for 2019, we cover several topics that have persisted over the past few years and identify new issues that will shape the scope of enforcement efforts for the remainder of this year and beyond. In this Quarterly Roundup, we discuss DOJ’s guidance on compliance programs and cooperation credit,...
Continue Reading
Recent Developments on the Fair Market Value Front – Part 1
By David Quinn Gacioch on Oct 3, 2017
Posted In Anti-Kickback Statute / Stark Law, Pharmaceuticals
Over the last several months, a handful of federal court decisions—including two rulings this summer on challenges to the admissibility of proposed expert testimony—serve as reminders of the importance of (and parameters around) fair market value (FMV) issues in the context of the Anti-Kickback Statute (AKS) and the False Claims Act (FCA). First, a quick...
Continue Reading
Motions in Limine Filed in Lance Armstrong/US Postal Service Litigation Raise FCA Damages, Government Knowledge and Relator Character Issues on Which Court’s Rulings May Have Widespread Impact
By David Quinn Gacioch on Jul 6, 2017
Posted In Damages and Penalties, Government Knowledge
We reported back in March on the US District Court for the District of Columbia’s summary judgment decision in the Lance Armstrong/Floyd Landis/US Postal Service (USPS) False Claims Act (FCA) litigation, centered on Lance Armstrong’s use of performance enhancing drugs (PEDs) while he was leading a professional cycling team sponsored by the USPS. A pack...
Continue Reading
In Calculating FCA Damages, Another Court Rejects Government Windfalls Based on Purportedly “Tainted Claims”
By David Quinn Gacioch on Mar 29, 2017
Posted In Damages and Penalties
Last month, the US District Court for the District of Columbia delivered another blow to the “tainted claims” theory of False Claims Act (FCA) damages frequently espoused by the government and qui tam relators. From the 1990s through 2004, the US Postal Service sponsored a professional cycling team led by Lance Armstrong, who won the...
Continue Reading
